2 Upcoming Catalysts for Amarin

Biotech Amarin (NASDAQ: AMRN  ) has slide more than 20% since launching its hypertriglyceridemia drug Vascepa in January. The company's market value has dropped following months of indecision regarding the drug's exclusivity status and question marks over the drug's launch. As the stock continues to be hotly debated, there are two catalysts in particular that investors should watch. Health-care analyst Max Macaluso discusses each in the following video.

Can Amarin beat the odds?
Small biotech companies usually crash and burn when it comes to launching drugs -- but can Amarin prove the doubters wrong with its new lipid-lowering drug? In our new premium research report, The Motley Fool's top biotech analyst offers an in-depth look at this drugmaker's upcoming opportunities, along with reasons to buy and sell this stock today. To find out more, simply click here now to claim your copy.

Editor's Note: At 1:00, the speaker meant to say eight months.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2385236, ~/Articles/ArticleHandler.aspx, 11/24/2014 4:48:03 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement